Clinical Trial Update: Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and efficacy of an ESC-derived dopamine progenitor cell therapy in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ESC-derived dopamine progenitor cell therapy

Snippet

Sponsor: S.Biomedics Co., Ltd. | Conditions: Parkinson's Disease | Phase 1, Phase 2 | Status: COMPLETED